What is the recommended acyclovir dosing regimen for pediatric patients with herpes simplex virus (HSV) or varicella‑zoster virus (VZV) infections, including oral and intravenous routes and adjustments for renal impairment?

Acyclovir Dosing in Pediatric Patients

For pediatric HSV and VZV infections, acyclovir dosing must be weight-based and adjusted according to disease severity, infection site, and renal function, with IV doses ranging from 5-20 mg/kg every 8 hours and oral doses of 20 mg/kg (max 400-800 mg) given 3-5 times daily depending on the specific indication.

Herpes Simplex Virus (HSV) Infections

CNS or Disseminated Disease

For HSV encephalitis or disseminated disease in children outside the neonatal period, administer acyclovir 10 mg/kg IV every 8 hours for 21 days 1. The FDA label specifies 10 mg/kg IV every 8 hours for 10 days in HSV encephalitis for patients 12 years and older, but 20 mg/kg IV every 8 hours for 10 days in children 3 months to 12 years 2. However, British guidelines recommend 14-21 days of treatment, with a minimum of 21 days for children aged 3 months to 12 years due to relapse rates as high as 26-29% 1.

• Repeat CSF HSV DNA PCR at days 19-21 of therapy; do not discontinue acyclovir until CSF PCR is negative 1
• Some experts use body surface area dosing (500 mg/m² IV every 8 hours) instead of weight-based dosing in children >1 year 1

Neonatal HSV Infections (Birth to 3 Months)

For neonatal HSV, administer acyclovir 20 mg/kg IV every 8 hours for 14 days for skin/eye/mouth disease, or 21 days for CNS disease 1, 2. The FDA label notes that doses of 15-20 mg/kg have been used, though safety and efficacy are not fully established 2. Recent evidence suggests higher doses (20 mg/kg) for 21 days decrease mortality to 5% with better neurodevelopmental outcomes 1.

Mucocutaneous HSV Infections

For moderate to severe gingivostomatitis:

• Start with acyclovir 5-10 mg/kg IV every 8 hours 1
• After lesions begin to regress, switch to oral acyclovir and continue until complete healing 1

For mild gingivostomatitis or genital herpes:

• Children <45 kg: acyclovir 20 mg/kg (max 400 mg/dose) orally 3 times daily for 5-14 days 1
• Adolescents ≥45 kg: acyclovir 400 mg orally twice daily for 5-14 days 1

For immunocompromised patients with mucocutaneous HSV:

• Children <12 years: 10 mg/kg IV every 8 hours for 7 days 2
• Adolescents ≥12 years: 5 mg/kg IV every 8 hours for 7 days 2

Varicella-Zoster Virus (VZV) Infections

Chickenpox (Varicella)

For immunocompromised children with chickenpox, administer acyclovir 20 mg/kg (max 800 mg/dose) orally 4 times daily for 7-10 days or until no new lesions for 48 hours 1. For severe immune suppression or complicated cases, use 10 mg/kg IV every 8 hours 1.

• Treatment should be initiated within 24 hours of rash onset for maximum benefit 3
• For children with normal or moderate immune suppression and mild disease, oral therapy is appropriate 1

Herpes Zoster (Shingles)

For immunocompromised children with zoster:

• Children <12 years: 20 mg/kg IV every 8 hours for 7 days 2
• Adolescents ≥12 years: 10 mg/kg IV every 8 hours for 7 days 2

For immunocompetent children with zoster, oral acyclovir 20 mg/kg (max 800 mg/dose) 4 times daily for 7-10 days may be beneficial 1, particularly if started within 48-72 hours of rash onset 1.

VZV Retinal Infections

For acute retinal necrosis, administer acyclovir 10 mg/kg IV every 8 hours for 10-14 days, followed by oral valacyclovir 1 g three times daily for 4-6 weeks (for adolescents able to take adult dosing) or oral acyclovir 20 mg/kg for 4-6 weeks 1.

Renal Impairment Adjustments

Acyclovir dosing must be adjusted for renal impairment as it is primarily renally excreted (62-91% unchanged) 2. The FDA provides specific adjustments 2:

• CrCl >50 mL/min/1.73m²: 100% dose every 8 hours
• CrCl 25-50 mL/min/1.73m²: 100% dose every 12 hours
• CrCl 10-25 mL/min/1.73m²: 100% dose every 24 hours
• CrCl 0-10 mL/min/1.73m²: 50% dose every 24 hours

For hemodialysis patients, administer an additional dose after each dialysis session 2. Recent pharmacokinetic studies show that children with augmented renal clearance (eGFR >250 mL/min/1.73m²) may require doses of 15-20 mg/kg every 6 hours to maintain therapeutic levels 4.

Special Populations and Considerations

Neonates and Premature Infants

Acyclovir clearance is significantly reduced in neonates, particularly those <34 weeks post-menstrual age, with elimination half-life ranging from 10-15 hours in the first month of life decreasing to 2.5 hours thereafter 5, 6. Dosing adjustments based on post-menstrual age and creatinine clearance are essential 5.

Oral Bioavailability

Oral acyclovir bioavailability is only 10-20% and decreases with increasing dose 3, 6. For VZV infections requiring higher drug exposure, oral doses must be substantially higher than for HSV (800 mg vs 400 mg in adults) 7. Pharmacokinetic studies suggest that for VZV treatment in children >3 months, a twofold increase in standard oral dosing may be necessary 6.

Acyclovir-Resistant Infections

For acyclovir-resistant HSV or VZV, use foscarnet 40 mg/kg IV every 8 hours or 60 mg/kg IV every 12 hours 1. Resistance typically occurs in immunocompromised patients with prolonged exposure 8, 9.

Critical Safety Considerations

Maintain adequate hydration and monitor renal function, as acyclovir can cause reversible nephropathy from crystalluria in up to 20% of patients, typically after 4 days of IV therapy 1. Never administer acyclovir as rapid IV bolus; infuse over 1 hour at concentrations ≤7 mg/mL to minimize phlebitis risk 2.

Maximum dose should not exceed 20 mg/kg every 8 hours for any pediatric patient 2. For obese patients, dose based on ideal body weight 2.